Human Genome Epidemiology Literature Finder
Records 1 - 20 (of 20 Records) |
Query Trace: Death and KEAP1[original query] |
---|
Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 7 14 (11): 1924-1934. Goeman Frauke, De Nicola Francesca, Scalera Stefano, Sperati Francesca, Gallo Enzo, Ciuffreda Ludovica, Pallocca Matteo, Pizzuti Laura, Krasniqi Eriseld, Barchiesi Giacomo, Vici Patrizia, Barba Maddalena, Buglioni Simonetta, Casini Beatrice, Visca Paolo, Pescarmona Edoardo, Mazzotta Marco, De Maria Ruggero, Fanciulli Maurizio, Ciliberto Gennaro, Maugeri-Saccà Marcel |
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. International journal of cancer 2019 Oct . Qian Jie, Nie Wei, Lu Jun, Zhang Lele, Zhang Yanwei, Zhang Bo, Wang Shuyuan, Hu Minjuan, Xu Jianlin, Lou Yuqing, Dong Yu, Niu Yanjie, Yan Bo, Zhong Runbo, Zhang Wei, Chu Tianqing, Zhong Hua, Han Baoh |
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Annals of oncology : official journal of the European Society for Medical Oncology 2020 Aug . Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Filetti M, Giusti R, Vecchione A, Occhipinti M, Gelibter A, Botticelli A, De Nicola F, Ciuffreda L, Goeman F, Gallo E, Visca P, Pescarmona E, Fanciulli M, De Maria R, Marchetti P, Ciliberto G, Maugeri-Saccà |
Exome sequencing identifies somatic mutations in novel driver genes in non-small cell lung cancer. Aging 2020 Jul 12 . Zhang Manman, Zhang Lele, Li Yan, Sun Feng, Fang Ya, Zhang Ruijia, Wu Jin, Zhou Guanbiao, Song Huaidong, Xue Liqiong, Han Bing, Zheng Cuix |
NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. The oncologist 2020 4 25 (6): e955-e963. Xu Xian, Yang Yang, Liu Xiaoyan, Cao Na, Zhang Peng, Zhao Songhui, Chen Donglin, Li Li, He Yong, Dong Xiaowei, Wang Kai, Lin Hanqing, Mao Naiquan, Liu Lingxia |
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. Scientific reports 2020 Nov 10 (1): 20243. Shang Yanhong, Li Xiaofang, Liu Weiwei, Shi Xiaoliang, Yuan Shaohua, Huo Ran, Fang Guotao, Han Xiao, Zhang Jingnan, Wang Kunjie, Dou Zhengyue, Zhang Yan, Zang Aimin, Zhang L |
A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. Frontiers in immunology 2021 7 12 606027. Lin Jiamao, Wang Xiaohui, Zhang Chenyue, Bu Shuai, Zhao Chenglong, Wang Haiyo |
Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. Cancers 2021 Mar 13 (6): . Zhu Guangsheng, Ren Dian, Lei Xi, Shi Ruifeng, Zhu Shuai, Zhou Ning, Zu Lingling, Mello Ramon Andrade De, Chen Jun, Xu So |
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation. Oncoimmunology 2021 2 10 (1): 1865670. Nie Wei, Gan Lu, Wang Xin, Gu Kai, Qian Fang-Fei, Hu Min-Juan, Zhang Ding, Chen Shi-Qing, Lu Jun, Cao Shu-Hui, Li Jing-Wen, Wang Yue, Zhang Bo, Wang Shu-Yuan, Li Chang-Hui, Yang Ping, Xu Mi-Die, Zhang Xue-Yan, Zhong Hua, Han Bao-H |
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Nov . Ricciuti Biagio, Arbour Kathryn C, Lin Jessica J, Vajdi Amir, Vokes Natalie, Hong Lingzhi, Zhang Jianjun, Tolstorukov Michael Y, Li Yvonne Y, Spurr Liam F, Cherniack Andrew D, Recondo Gonzalo, Lamberti Giuseppe, Wang Xinan, Venkatraman Deepti, Alessi Joao V, Vaz Victor R, Rizvi Hira, Egger Jacklynn, Plodkowski Andrew J, Khosrowjerdi Sara, Digumarthy Subba, Park Hyesun, Vaz Nuno, Nishino Mizuki, Sholl Lynette M, Barbie David, Altan Mehmet, Heymach John V, Skoulidis Ferdinandos, Gainor Justin F, Hellmann Matthew D, Awad Mark |
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Translational lung cancer research 2020 Dec 9 (6): 2367-2379. Xu Yanjun, Li Hui, Huang Zhiyu, Chen Kaiyan, Yu Xiaoqing, Sheng Jiamin, Zhang Han-Han, Fan Y |
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC. JTO clinical and research reports 2022 Sep 3 (9): 100390. Cooper Alissa J, Muzikansky Alona, Lennerz Jochen, Narinesingh Farhaana, Mino-Kenudson Mari, Hung Yin P, Piotrowska Zofia, Dagogo-Jack Ibiayi, Sequist Lecia V, Gainor Justin F, Lin Jessica J, Heist Rebecca |
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung cancer (Amsterdam, Netherlands) 2022 Jun 170 114-121. Cordeiro de Lima Vladmir C, Corassa Marcelo, Saldanha Erick, Freitas Helano, Arrieta Oscar, Raez Luis, Samtani Suraj, Ramos Maritza, Rojas Carlos, Burotto Mauricio, Chamorro Diego F, Recondo Gonzalo, Ruiz-Patiño Alejandro, Más Luis, Zatarain-Barrón Lucia, Mejía Sergio, Nicolas Minata José, Martín Claudio, Bautista Blaquier Juan, Motta Guerrero Rodrigo, Aliaga-Macha Carlos, Carracedo Carlos, Ordóñez-Reyes Camila, Garcia-Robledo Juan Esteban, Corrales Luis, Sotelo Carolina, Ricaurte Luisa, Santoyo Nicolas, Cuello Mauricio, Jaller Elvira, Rodríguez July, Archila Pilar, Bermudez Maritza, Gamez Tatiana, Russo Alessandro, Viola Lucia, Malapelle Umberto, de Miguel Perez Diego, Rolfo Christian, Rosell Rafael, Cardona Andrés |
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Journal for immunotherapy of cancer 2022 02 10 (2): . West Howard Jack, McCleland Mark, Cappuzzo Federico, Reck Martin, Mok Tony Sk, Jotte Robert M, Nishio Makoto, Kim Eugene, Morris Stefanie, Zou Wei, Shames David, Das Thakur Meghna, Shankar Geetha, Socinski Mark |
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO precision oncology 2022 1 5 153-162. Padda Sukhmani K, Aredo Jacqueline V, Vali Shireen, Singh Neeraj K, Vasista Sumanth M, Kumar Ansu, Neal Joel W, Abbasi Taher, Wakelee Heather |
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC. Genes & diseases 2022 1 9 (1): 245-251. Wang Shuhang, Jiang Miaomiao, Yang Zuozhen, Huang Xiaoyun, Li Ni |
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. BMC cancer 2023 4 23 (1): 352. Julian Cristina, Pal Navdeep, Gershon Anda, Evangelista Marie, Purkey Hans, Lambert Peter, Shi Zhen, Zhang Qi |
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab. JAMA network open 2023 1 6 (1): e2249591. Lebow Emily S, Shepherd Annemarie, Eichholz Jordan E, Offin Michael, Gelblum Daphna Y, Wu Abraham J, Simone Charles B, Schoenfeld Adam J, Jones David R, Rimner Andreas, Chaft Jamie E, Riaz Nadeem, Gomez Daniel R, Shaverdian Nar |
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology 2023 1 . Mok T S K, Lopes G, Cho B C, Kowalski D M, Kasahara K, Wu Y-L, de Castro G, Turna H Z, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza M C, Piperdi B, Herbst R |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: